Sepsia Therapeutics is pioneering innovative therapies aimed at combating sepsis, a severe condition resulting from the body's response to infections, particularly those caused by bacteria and fungi. The company focuses on harnessing the host's scavenger-like receptors found on lymphocyte surfaces, which are capable of binding to and neutralizing harmful microbial structures known as Pathogen-Associated Molecular Patterns (PAMPs). This approach targets both the virulence factors of pathogens and the inflammatory responses they provoke, offering a novel strategy to address the rising incidence of sepsis, especially in the context of increasing multidrug-resistant (MDR) infections. By developing non-antibiotic therapies, Sepsia Therapeutics aims to mitigate the limitations of traditional antibiotic treatments, which are becoming less effective against resistant strains.

The company's flagship product, SIXTIDE, is a biological drug that encompasses a range of therapeutic modalities, including injectable peptides derived from human scavenger receptors, adoptive cell therapies utilizing Chimeric Antigen Receptors (CARs), and medical devices designed for hemadsorption of microbial toxins. These therapies are designed to inhibit the pro-inflammatory effects of pathogens, enhance the immune response against infections, and reduce the overall microbial load in patients suffering from sepsis. By focusing on the dual challenge of infection and inflammation, Sepsia Therapeutics is positioned to transform the treatment landscape for sepsis, providing alternatives to conventional antibiotic therapies and addressing the urgent need for effective interventions in this critical area of healthcare.

Spain

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Our strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators.

Sepsia Therapeutics

Company Details